A. D'Urzo
- Confirmation of asthma diagnosis in the communityBy A. D'Urzo
- Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?By C. Vogelmeier, A. D'Urzo, R. Pauwels†, J. M. Merino, M. Jaspal, S. Boutet, I. Naya and D. PriceC. VogelmeierA. D'UrzoR. Pauwels†J. M. MerinoM. JaspalS. BoutetI. Naya
- NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: The GLOW1 trialBy A. D'Urzo, G. Ferguson, C. Martin, Y. Lu, D. Banerji and T. OverendA. D'Urzo1Department of Family and Community Medicine, University of Toronto, ON, CanadaG. Ferguson2Respiratory Medicine, Pulmonary Research Institute of Southeast Michigan, Livonia, MI, United StatesC. Martin3Respiratory Medicine, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomY. Lu4Respiratory Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesD. Banerji4Respiratory Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesT. Overend3Respiratory Medicine, Novartis Horsham Research Centre, Horsham, West Sussex, United Kingdom
- NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trialBy J.A. van Noord, K. Hirata, A. D'Urzo, C. Martin, R. Horton, Y. Lu and T. OverendJ.A. van Noord1Respiratory Medicine, Atrium Medisch Centrum, Heerlen, NetherlandsK. Hirata2Respiratory Medicine, Osaka City University, Abeno-ku, Osaka, JapanA. D'Urzo3Department of Family and Community Medicine, University of Toronto, ON, CanadaC. Martin4Respiratory Medicine, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomR. Horton4Respiratory Medicine, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomY. Lu5Respiratory Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesT. Overend4Respiratory Medicine, Novartis Horsham Research Centre, Horsham, West Sussex, United Kingdom
- NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: The GLOW1 trialBy A. D'Urzo, G. Ferguson, M. Kato, S. Atis, C. Martin, V.K.T. Alagappan, D. Banerji, Y. Lu and T. OverendA. D'Urzo1Department of Family and Community Medicine, University of Toronto, ON, CanadaG. Ferguson2Respiratory Medicine, Pulmonary Research Institute of Southeast Michigan, Livonia, MI, United StatesM. Kato3Respiratory Medicine, Kishiwada City Hospital, Osaka, JapanS. Atis4Faculty of Medicine, Mersin University, Icel, TurkeyC. Martin5Respiratory Medicine, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomV.K.T. Alagappan5Respiratory Medicine, Novartis Horsham Research Centre, Horsham, West Sussex, United KingdomD. Banerji6Respiratory Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesY. Lu6Respiratory Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesT. Overend5Respiratory Medicine, Novartis Horsham Research Centre, Horsham, West Sussex, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
